CASE: We describe two cases in which treatment with aprepitant persistently altered antithrombotic control in patients receiving warfarin. A 60-year-old man received 5 weekly cycles of chemotherapy. Aprepitant was administered as a 3-day regimen from the second cycle of chemotherapy. In each of the chemotherapy cycles that included aprepitant, the therapeutic international normalized ratio (INR) decreased markedly to <1.6, and slowly recovered over several weeks. A 47-year-old woman was treated with 4 weekly cycles of chemotherapy. Aprepitant was administered as a 3-day regimen. On day 8 of the first cycle of chemotherapy, the patient's INR fell markedly to 1.1. Although warfarin dosage was steadily increased over the four subsequent cycles of chemotherapy, therapeutic target range was not recovered. INR gradually returned to normal during the 2 months after the final cycle of chemotherapy. CONCLUSION: To our knowledge, this is the first case report to document the effects of aprepitant in cancer patients receiving anticoagulation therapy.
CASE: We describe two cases in which treatment with aprepitant persistently altered antithrombotic control in patients receiving warfarin. A 60-year-old man received 5 weekly cycles of chemotherapy. Aprepitant was administered as a 3-day regimen from the second cycle of chemotherapy. In each of the chemotherapy cycles that included aprepitant, the therapeutic international normalized ratio (INR) decreased markedly to <1.6, and slowly recovered over several weeks. A 47-year-old woman was treated with 4 weekly cycles of chemotherapy. Aprepitant was administered as a 3-day regimen. On day 8 of the first cycle of chemotherapy, the patient's INR fell markedly to 1.1. Although warfarin dosage was steadily increased over the four subsequent cycles of chemotherapy, therapeutic target range was not recovered. INR gradually returned to normal during the 2 months after the final cycle of chemotherapy. CONCLUSION: To our knowledge, this is the first case report to document the effects of aprepitant in cancerpatients receiving anticoagulation therapy.
Authors: S Gerbal-Chaloin; J M Pascussi; L Pichard-Garcia; M Daujat; F Waechter; J M Fabre; N Carrère; P Maurel Journal: Drug Metab Dispos Date: 2001-03 Impact factor: 3.922
Authors: M Depré; A Van Hecken; M Oeyen; I De Lepeleire; T Laethem; P Rothenberg; K J Petty; A Majumdar; T Crumley; D Panebianco; A Bergman; J N de Hoon Journal: Eur J Clin Pharmacol Date: 2005-06-28 Impact factor: 2.953
Authors: Paul J Hesketh; Steven M Grunberg; Richard J Gralla; David G Warr; Fausto Roila; Ronald de Wit; Sant P Chawla; Alexandra D Carides; Juliana Ianus; Mary E Elmer; Judith K Evans; Klaus Beck; Scott Reines; Kevin J Horgan Journal: J Clin Oncol Date: 2003-10-14 Impact factor: 44.544
Authors: Craig R Shadle; Yih Lee; Anup K Majumdar; Kevin J Petty; Cynthia Gargano; Thomas E Bradstreet; Judith K Evans; Robert A Blum Journal: J Clin Pharmacol Date: 2004-03 Impact factor: 3.126
Authors: Philip L Mar; Rakesh Gopinathannair; Brooke E Gengler; Mina K Chung; Arturo Perez; Jonathan Dukes; Michael D Ezekowitz; Dhanunjaya Lakkireddy; Gregory Y H Lip; Mike Miletello; Peter A Noseworthy; James Reiffel; James E Tisdale; Brian Olshansky Journal: Circ Arrhythm Electrophysiol Date: 2022-05-27